Global Thyroid Cancer Drugs Market Report 2021: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib –


DUBLIN – (COMMERCIAL THREAD) – The report “Global Thyroid Cancer Drugs Market Report 2021: Impact and Recovery from COVID-19 to 2030” has been added to offer

The major players in the thyroid cancer drugs market are Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co., Teva parenteral Medicines Inc. and Jerome Stevens Pharmaceuticals Inc.

The global thyroid cancer drugs market is expected to grow from $ 0.4 billion in 2020 to $ 0.47 billion in 2021 at a compound annual growth rate (CAGR) of 17.5%. The growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, remote working and the closure of business activities which resulted in operational challenges. The market is expected to reach $ 0.98 billion in 2025 at a CAGR of 20.2%.

The thyroid cancer drugs market includes sales of drugs used to treat thyroid cancer. Thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops. Types of thyroid cancer include follicular, papillary, medullary, anaplastic, and thyroid lymphoma.

The manufacturers of thyroid cancer drugs are regulated by regulatory authorities such as the Food and Drug Administration in the United States. For example, the off-label use of drugs approved by the FDA for the treatment of cancer requires FDA approval. Manufacturers are required to submit an additional marketing application called a Supplemental New Drug Application (sNDA) to the FDA that approves the drug for prescription.

The growing use of targeted therapies for the treatment of thyroid cancer is slowing the market for thyroid cancer drugs. Targeted therapies target specific cancer genes, proteins and tissues that promote cancer growth and survival. Targeted therapies are increasingly used to treat thyroid cancer because thyroid hormone treatments, including radioactive iodine therapy, are not effective against these cancers.

For example, vandetanib (Caprelsa) and cabozantinib (Cometriq) are targeted therapies used to treat advanced medullary thyroid cancer (MTC). As patients increasingly use targeted therapies for treatment, the demand for thyroid cancer drugs is decreasing, affecting the growth of the market.

Combination drugs are increasingly used in the treatment of thyroid cancer because they are more effective and help prevent cancer progression. A combined drug comprises at least two active pharmaceutical ingredients (APIs) combined into a single dosage form. These drugs reduce the development of drug resistance and prevent the growth of cancer cells. For example, the FDA has approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), an MEK inhibitor for the treatment of anaplastic thyroid cancer.

The increasing incidence of thyroid cancer, especially among women, is driving the thyroid cancer drug market. According to the American Cancer Society, women are three times more likely to develop thyroid cancer than men.

Thyroid cancer is growing at a rapid rate and an estimated 52,070 new cases of thyroid cancer will be discovered in the United States in 2019 and that 2,170 deaths will occur from the disease. The increase in thyroid cancer can be attributed to radiation exposure, a family history of goiter, and certain inherited syndromes.

Main topics covered:

1. Summary

2. Characteristics of Thyroid Cancer Drugs Market

3. Thyroid Cancer Drugs Market Trends and Strategies

4. Impact of COVID-19 on thyroid cancer drugs

5. Size and Growth of Thyroid Cancer Drugs Market

5.1. Global Historical Thyroid Cancer Drugs Market, 2015-2020, in USD Billion

5.1.1. Market drivers

5.1.2. Market restrictions

5.2. Global Thyroid Cancer Drugs Forecast Market, 2020-2025F, 2030F, in USD Billion

5.2.1. Market drivers

5.2.2. Market constraints

6. Thyroid Cancer Drugs Market Segmentation

6.1. Global thyroid cancer drugs market, segmentation by drug type, history and forecast, 2015-2020, 2020-2025F, 2030F, in USD billion

  • Ipilimumab

  • Cabozantinib-S-malate

  • Caprelsa (Vandetanib)

  • Doxorubicin hydrochloride

  • Lenvatinib mesylate

  • Nivolumab

  • Vandetanib

  • Others

6.2. Global thyroid cancer drugs market, segmentation by end users, history and forecast, 2015-2020, 2020-2025F, 2030F, billion dollars

  • Hospitals

  • Oncology clinics

  • Research organizations

  • Others

6.3. Global Thyroid Cancer Drugs Market, Segmentation by Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

  • Radioactive iodine ablation

  • Thyroid Stimulating Hormone (HRT) Suppression

  • Chemotherapy

  • Targeted multikinase therapy

  • Others

7. Regional and Country Analysis of Thyroid Cancer Drugs Market

7.1. Global thyroid cancer drugs market, divided by region, historical and forecast, 2015-2020, 2020-2025F, 2030F, in USD billion

7.2. Global thyroid cancer drugs market, divided by country, historical and forecast, 2015-2020, 2020-2025F, 2030F, in USD billion

Companies mentioned

  • Mylan Pharma inc.

  • Alara Pharmaceutical Company

  • Bristol Myers co.

  • Parenteral Drugs Teva Inc.

  • Jérôme Stevens Pharmaceuticals Inc.

  • Baxter International Inc.

  • Abbott Laboratories

  • Pharmaceutical App llc.

  • AstraZeneca SA

  • GlaxoSmithKline plc

  • Exelixis inc.

  • Novartis AG

  • Pfizer Inc.

  • Biovista

  • Vascular biogenesis

  • Azaya Therapeutics

  • Bionomy

  • Bayer

  • Eisai

  • Bio-Path Holdings

  • Pharmaceutical company Takeda

For more information on this report, visit

Source link

Leave A Reply

Your email address will not be published.